Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
about
Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients.Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.Management of cytomegalovirus infection in haemopoietic stem cell transplantation.
P2860
Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Valganciclovir as pre-emptive ...... em cell transplant recipients.
@en
Valganciclovir as pre-emptive ...... em cell transplant recipients.
@nl
type
label
Valganciclovir as pre-emptive ...... em cell transplant recipients.
@en
Valganciclovir as pre-emptive ...... em cell transplant recipients.
@nl
prefLabel
Valganciclovir as pre-emptive ...... em cell transplant recipients.
@en
Valganciclovir as pre-emptive ...... em cell transplant recipients.
@nl
P2093
P50
P356
P1433
P1476
Valganciclovir as pre-emptive ...... tem cell transplant recipients
@en
P2093
Albert Pahissa
Antonio Torres
Cristina Barrenetxea
Ildefonso Espigado
Isidro Jarque
Jose Maria Aguado
Julián de la Torre
Manuela Aguilar
Mercedes Gurguí
Montserrat Batlle
P304
P356
10.3851/IMP1858
P577
2011-01-01T00:00:00Z